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Abstract
Bereaved spouses or partners are thought to be at increased risk of morbidity and mortality. However, there are few large
prospective studies and results are inconsistent. We estimated the relative mortality, prescription of psychotropic
medication and use of primary medical care services in adults whose cohabitee died of cancer. To do this, we undertook a
cohort study using The Health Improvement Network (THIN) UK primary care database. Participants were 1) people aged
over 40, who were registered with general practices and had been exposed to the death of a cohabitee from cancer; and 2)
a comparison cohort frequency matched on five year age bands and sex who were cohabiting with a living partner. The
baseline was chosen as six months before the date of the cancer death for the exposed group and a random date for the
unexposed group. Incidence rate ratios (IRR) with 95% confidence intervals (CI) were estimated using random effects
Poisson regression to account for clustering within general practices and adjusting for other key variables. 92,129 patients
were studied for a median follow up of 4 years. Cohabitees of patients who died of cancer were less likely to die of any
cause (IRR 0.71, CI 0.68–0.74) after adjustment for age, gender, number of non-psychotropic prescriptions 6 months before
the cancer death/index date, use of psychotropic medication 6 months before the cancer death/index date, smoking,
alcohol and area deprivation score. Exposed patients were more likely to receive a prescription for antidepressant or
hypnotic medication and to attend their GP both before and after the death of the cohabitee. In conclusion, we did not
confirm increased mortality in cohabitees of people dying from cancer.
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Introduction
Grief is the constellation of psychological and physical reactions
to the death of a spouse, relative, child or friend [1–3].
Bereavement is a universal experience and is viewed by the public
as the most stressful of all life events [3]. It has long been
recognised that it may place older spouses and partners at risk of
adverse outcomes including increased morbidity and mortality [2].
Possible reasons for elevated mortality have included emotional
stress and its somatic consequences, shared environmental risk
factors such as smoking or diet, increased use of alcohol and
recreational drugs, and poor self and/or health care following
bereavement. However, there are few large scale prospective
studies of the health outcome of spouses and partners bereaved by
cancer and results are inconsistent.
Grief is a complex process. The early effects for a person who
loses a partner or spouse concern a) the immediate shock and
psychological impact of bereavement and b) the change from
cohabitee/married to single status [4]. Although depression or
other psychological distress may diminish over the first year,
distress over the loss itself may continue for a number of years [5]
and include deterioration in morale and in physical health. In
studying the impact of bereavement on longer term physical health
it is important to distinguish any such changes from normal age
related deterioration, and thus controlled comparisons are
essential. The clearest evidence for increased mortality arises from
a study of members of a health care plan in California in which
12,522 spouse pairs were followed up for 23 years. Mortality
following bereavement was significantly higher in men and women
after adjusting for age, education, and other predictors of
mortality. The highest relative risks occurred 7–12 months after
bereavement but remained elevated for two years after the
bereavement [6]. The study, however, was unable to adjust for
other important changes in health status in the ‘‘to-be bereaved’’
or those that might have occurred between the baseline
examination and mortality, possibly weakening the relationship
between risk factors other than bereavement and mortality. Other
studies have reported absent or statistically weaker associations. A
large cohort study of 7,735 men followed for a mean of 11.5 years
in the United Kingdom showed no association between becoming
widowed and subsequent cardiovascular or non-cardiovascular
(usually cancer) death [7]. This was in contrast to men divorced
during follow-up who were at elevated risk of both types of
mortality. A further study of data on almost 92,000 people in the
US identified 4,032 white adults who became widowed between
1963 and 1974. It was reported that mortality rates based on
person-years at risk were not elevated for widows compared to
matched controls remaining married, while the relative risk was
significant for men in only those 55 years old and over [8].
Another large US study of mortality over 11 years estimated that
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the relative risk of mortality was greater for unmarried versus
married partners from all ethnic backgrounds [9]. Unfortunately
this study did not compare mortality in all bereaved participants
versus those not bereaved.
The mechanisms involved in men’s particular vulnerability are
not clear short of the somewhat prosaic suggestions that men are
less able to prepare nutritious meals and are more likely to smoke
and misuse alcohol. In order to explore whether sex differences in
such factors after bereavement might explain higher risk in
widowers than widows, data were examined from a national
register in Denmark of over 6,000 bereavements [10]. Although
daily use of medication and primary care visits rose for up to five
years after bereavement, no differences between men and women
were found. However, a number of other studies have reported
age and gender differences in vulnerability to bereavement [11–
13].
Given these varying results, we undertook a study of bereave-
ment using The Health Improvement Network (THIN), a national
primary care database in the UK. Our key objectives were to
estimate 1) the mortality, 2) prescription of psychotropic medica-
tion and 3) use of general practice services in adults whose
cohabitee died of cancer and compare them to a cohort of
individuals of similar age and gender who continued to cohabit
with another adult. We selected one particular type of illness
(cancer) to reduce some of the variability inherent in the data.
These are patients and families who receive many similar types of
treatment support and for whom the death is expected to some
degree.
Methods
Ethics statement
The THIN scheme for obtaining and providing anonymous
patient data to researchers was approved by the National Health
Service South-East Multicenter Research Ethics Committee
(MREC) in 2002.
Data source
The Health Improvement Network (THIN) is a primary care
database of anonymous current and historical general practice
records from 1987 to the present day on more than 9 million
patients from nearly 500 practices in the UK (www.
cegedimstrategicdata.com). THIN is a well validated and widely
used source of real time clinical data which has extensively been
used for research purposes [14,15]. The database is based on
practices which use the Vision software to record patient care and
management. It includes information on patient demographic
details [date of birth, gender and social deprivation (quintiles of
Townsend deprivation scores)] as well as registration details.
Longitudinal data on diagnoses, symptoms, procedures, investiga-
tions and additional health information such as smoking and
substance use is largely recorded using Read codes a hierarchical
coding system [16], together with data on all prescriptions issued
(see below). Drugs prescribed are mapped to chapters in the British
National Formulary, so it is possible for researchers to select all (or
some if more appropriate) drugs from a given chapter. Each
patient also has a family number, which identifies people who are
living in the same household or otherwise are associated. The
database is broadly representative of UK general practices in
terms of patients’ age and sex, practice size and geographical
distribution [17]. Over 98% of the UK population is registered
with a general practitioner [18].
Practices and participants
As some practices did not use their computer systems fully in the
early 1990s we used data from practices from the time point where
they met our predefined criteria for acceptable computer usage:
that on average registered patients have at least one medical
record, one additional health record and at least two prescriptions
recorded per year [14,19]. Furthermore, it was a requirement that
practices recorded death as expected for the practice’s age and
gender distribution [20]. Exposed individuals were patients aged
over 40 who lived with someone who had died from cancer when
they were also aged over 40. Relatively few people die of cancer
below the age of 40, we therefore decided to focus our study on
those above that age. We avoided the death of children in families
by restricting the age gap between participant and bereaved to no
more than 15 years. Exposed patients were identified by first
extracting cancer deaths and subsequently identifying individuals
with the same family number registered with the general practice
at least six months before the death of the deceased. We restricted
the sample to those with at least 6 months data in order to have
sufficient data before the death against which to measure change.
We also restricted our sample to households with two adults with
less than a 15 year age gap between them, and up to four children
under the age of 18 years. This was to exclude instances where the
family number represents blocks of flats or residential homes.
We identified a comparison cohort of up to five unexposed for
each exposed individual using the same criteria except that their
cohabitee was still alive at a randomly chosen index date and
throughout the follow-up period. We needed to select a start point
for data collection for the unexposed group. However, given there
was no obvious date for the unexposed, we selected a random date
within the time period where they were registered with the GP, the
logic being that had their partner died it would have been on a
random date during their registration. The random date was
allocated by selecting time from a uniform distribution after the
time when data were of sufficient quality and the potential
unexposed patient and partner fulfilled the age criteria. We
stratified the sample in terms of sex and age (within five years age
bands) to ensure similar distributions amongst the two groups and
thereby gain greater statistical power. Patients were followed up
until they died, left the practice or end of data collection.
Exposure
The exposure was bereavement due to a cancer death.
Outcomes
Outcomes were mortality, courses of medication to alleviate
psychological distress and GP consultations after the cancer
death/index date.
Potential confounders
The following variables were included in the analyses as
potential confounders: age (five year age bands), gender, number
of general medicine prescriptions six months before the cancer
death/index date, and whether or not psychotropic medication
was prescribed [antidepressants, antipsychotics, hypnotics (yes/
no)] in the six months before the death. All prescribing is now
done through the practices’ computer systems and the classes of
prescribed drugs are arranged according to the chapters of the
UK’s British National Formulary. This includes obsolete medica-
tions, so patients prescribed drugs that are no longer possible to
prescribe are included in the data. Patients were classified as
current smokers or non-current smokers (to include ex-smokers).
Patients with missing smoking data (4%) were classified as non-
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current smokers. Excessive alcohol consumption was classified as
percentage of women who consumed over 14 units of alcohol per
week, and men who consumed over 21 units per week. We
assumed everyone else had within guidelines drinking habits,
which gave rise to no missing data. These data were taken from a
recording at any time, with the closest to the baseline being used.
These data are collected by the general practice staff at a new
patient health check on registration or if the information is
relevant to the disease for which the patient has consulted (e.g. if a
patient presents with respiratory symptoms, smoking status may be
enquired about). Other data may be part of the UK’s Quality
Outcomes Framework [21] for people with a number of chronic
conditions. These people are more likely to have such data
recorded than those without these conditions. For example if you
are a smoker you will be asked on regular interval whether you are
still smoking. However, this is not the case if you are a non-
smoker. In short, the vast majority of patients have at least one
measurement of these health indicators during the time they are
registered with a GP.
Statistical Analysis
The main outcomes were first examined using descriptive
statistics. We used the Kaplan-Meier estimator to estimate the
survival function of the exposed and unexposed cohort and crude
rates of mortality were compared. Crude mortality rates were
expressed as number of deaths per 1000 person years. Unadjusted
and adjusted incidence rate ratios (IRR) with 95% confidence
intervals were estimated for the association between bereavement
and the main outcomes. We used Poisson regression as the cohorts
in this study are dynamic i.e. patients register and leave the
practices at different time points. Random effect Poisson
regression also takes account of practice clustering. We tested
formally whether the effect of bereavement differed by age using a
log likelihood ratio test in the adjusted model. This determined
whether there was an interaction between age (dichotomised as
under or over 60) and whether the study population was part of
the exposed (to cancer death) or unexposed. Finally, we explored
whether mortality varied within the exposed group by gender. The
analysis was conducted using Stata 11.
Missing data
In clinical practice, patients often have measurements of blood
pressure, weight and height, alcohol consumption and smoking
status taken when they are relevant to current or future health
status. However, we found in another study that over two thirds
have these measurements taken in the first year after they register
with a general practice [22]. After the introduction of the Quality
Outcomes Framework the level of recording of these health
indicators has increased in particular for those who suffer from
chronic conditions included in that Framework. However, few
subjects in this study had missing data (e.g. only 4% had no
information available on smoking). For medical conditions and
prescriptions we assumed that if there was no record, the patient
had not had it within the relevant time window.
Results
Baseline characteristics
In total, there were 15,748 exposed individuals living with a
person diagnosed with cancer 6 months before their death and
76,381 unexposed individuals with an adult cohabitee at a random
index date. We cannot know how many participants were
excluded on the basis that they were potentially residing in flats
or residential homes as that criterion was a part of the extraction
algorithm – they were not all extracted first and then those in
group residences excluded. Table 1 shows the demographics and
other characteristics of the exposed and unexposed cohorts. The
first entry into the cohorts was in 1987 and the last exit was in
2010. Median duration of follow-up was four years. Mean ages
were identical in the exposed and unexposed groups (71, SD 10
years), while 10,308 (65%) of the exposed and 45,593 (60%) of the
unexposed were women. Ninety-eight per cent of exposed and
unexposed households contained opposite sex dyads. Twenty-eight
per cent of exposed households were in areas with a deprivation
score of 1 (least deprived) compared to 31% of the unexposed.
More of the exposed than unexposed households (10% vs. 7%)
were in the most deprived area. Prevalence of smoking was higher
in the exposed than unexposed group [3,099 (20%) vs. 12,012
(16%)] while excessive alcohol consumption was less frequent in
the exposed cohort [2,273 (14%) vs. 11,918 (16%)].
Findings for the 6 months before cancer death/index
date
In total, 12,756 (81%) of the exposed and 62,632 (82%) of the
unexposed received at least one prescription for a non-psychotro-
pic medication in the six months before the cancer death/index
date. The median numbers of prescriptions were also similar in
both groups [exposed group median 3 (25th and 75th centiles 1, 6)
and unexposed group 3 (1, 6)]. However, prescriptions for
psychotropic medications were higher in the exposed group
[hypnotics 1,503 (10%) vs. 4,379 (6%); antidepressants 1,983
(13%) vs. 7,361 (10%); and antipsychotic prescriptions 207 (1.3%)
vs. 866 (1.1%)]. Table 2 shows Incidence Rate Ratios (IRR) for
hypnotic, antidepressant and antipsychotic use, and GP consulta-
tions in the exposed and unexposed cohorts six months before the
cancer death/index date. Prescriptions for hypnotic (IRR 1.59,
95% CI 1.49–1.69) and antidepressant use (IRR 1.26, 1.20–1.33)
were significantly higher in the exposed group after adjustment but
there was no significant difference in antipsychotic use (IRR 1.09,
0.93–1.27). GP consultations were higher in the exposed
compared to the unexposed group (IRR 1.21, 1.20–1.22).
Psychotropic prescriptions and primary care
consultations after the death/index date
Patients exposed to the cancer death were significantly more
likely than comparison patients to receive new prescriptions for
hypnotics (IRR 2.44, 1.89–3.14) and antidepressants (IRR 1.87,
1.53–2.29) (Table 3). However, there was no significant difference
in new antipsychotic prescriptions (IRR 0.95, 0.49–1.84). Exposed
patients consulted their GPs slightly more frequently than
unexposed during follow-up (IRR 1.06, 1.06–1.07) (Table 3)
Mortality
All cause mortality was lower in the individuals whose spouse
died from cancer (exposed) (29.96 per 1000 person years) than in
those in the unexposed group (42.29 per 1000 person years)
(Figure 1) and this remained after adjustment (IRR 0.71, 0.68–
0.74). The effect of bereavement was the same across ages, in that
there was no interaction between age (over and below the age of
60 years) and exposure groups (p = 0.28).
Sex differences in mortality rates in the exposed cohort
Except for the youngest age group (40–49 years), men had
consistently higher mortality than women in each age group and
this became more marked with increasing age (Table 4).
Mortality after Bereavement
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Discussion
We found that individuals exposed to a cancer death had a
reduced risk of mortality 2) an increased likelihood of receiving a
new prescription for an antidepressant or hypnotic; and 3) a higher
consultation rate with the general practitioners during a median of
four years after the death of their partner. Psychotropic
medication was also more commonly prescribed to exposed
participants six months before the death strongly suggesting they
were already requiring help to cope with a stressful situation as
their cohabitee approached death. Our finding of a reduced
mortality after the death of a spouse, friend, partner or sibling runs
in contrast to some previous research. However, in this study we
focused on bereavement following a cancer death whereas
previous studies have not made this distinction.
Our finding of increased survival of a spouse or partner after a
cancer death is not completely counter-intuitive. The release from
the stress of caring may lead to better health and reduced
psychological morbidity for partners as the acute phase of grief
subsides. Furthermore, one possible explanation for our finding is
that many patients dying of cancer in the UK receive greater
supportive and palliative care services than those dying from other
causes and this may moderate cohabitees’ extreme stress [23] [24].
Where specialist rather than generalist palliative care is available,
carers may receive more direct support. Many community and
hospice based specialist palliative care teams conduct bereavement
risk assessments in relatives and friends of the dying [25,26]. Pre-
bereavement formal and informal counselling may be available for
families, and many palliative care services get back in touch with
families in the first few weeks of bereavement to offer further
support. This is particularly common practice in hospice settings,
and the majority of deaths in hospices are still due to cancer.
NICE guidelines in England and Wales for specialist palliative care
recommend carers are fully involved in clinical decisions and are
supported emotionally [27]. Death is also a more expected
outcome following a diagnosis of cancer. Those who have been
diagnosed early may have had considerable time to prepare for
death. People with cancer are more likely to be placed on registers
as part of the Gold Standards Framework, a structured care
Table 1. Description of exposed and unexposed cohorts.
Exposed Unexposed
Number of participants 15,748 76,381
Mean age (SD) 71 (10) 71 (10)
Women 10,308 (65%) 45,593 (60%)
Median (25thquartile, 75th quartile) follow-up time years 4.24 (1.81, 7.45) 3.99 (1.78,6.77)
Male/female pairs 15490 (98%) 74730 (98%)
Psychotropic medication Prescriptions issued 6 months before cancer
death date/index date1
Antipsychotic N (%) 207 (1%) 866 (1%)
Hypnotic N (%) 1,503 (10%) 4.379 (6%)
Antidepressant N (%) 1,983 (13%) 7,361 (10%)
Other prescriptions issued Median (25th percentile, 75th percentile)
number of prescriptions issued 6 months before cancer death date/
index date
3 (1,6) 3 (1,6)
Use of substances2
Current smokers 3,099 (20%) 12,012 (16%)
Excessive alcohol use3 2,273 (14%) 11,918 (16%)
Townsend Deprivation Score in quintiles: N (%)4
1 lowest deprivation 4,362 (28%) 23.724 (31%)
2 3.841 (24%) 19.694 (26%)
3 3.086 (20%) 14,768 (19%)
4 2.574 (16%) 10,671 (14%)
5 highest deprivation 1.552 (10%) 5,486 (7%)
1Expressed as the number who ever had a prescription over the 6 months.
2All available records of subjects were searched for information on substance use.
3Percentage of women who consumed .14 units of alcohol/week, and men who consumed .21 units/week.
42% of the exposed and 3% of the unexposed did not have data on deprivation.
doi:10.1371/journal.pone.0052561.t001
Table 2. Prescription of psychotropic medication and
consultations with GP over 6 months before cancer death/
index date.
Baseline
Unadjusted IRR
(95%CI)*
Adjusted IRR
(95%CI)*#
Hypnotic use 1.69 (1.59–1.79) 1.59 (1.49–1.69)
Antidepressant use 1.33 (1.27–1.40) 1.26 (1.20–1.33)
Antipsychotic use 1.16 (0.99–1.35) 1.09 (0.93–1.27)
Consultations with GP 1.21 (1.20–1.22) 1.18 (1.17–1.18)
*Reference group unexposed.
#Adjusted for age, gender, number of non-psychotropic prescriptions,
smoking, alcohol and deprivation score.
doi:10.1371/journal.pone.0052561.t002
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programme in UK general practice http://www.
goldstandardsframework.org.uk/), and be offered opportunities
to discuss future care planning and preferred priorities for care and
place of death. Furthermore, cancer may be distinct from other
causes of mortality in that life habits (except possibly smoking)
might not be shared between partners as is often the case for
COPD, and heart and liver disease. However, even if we are
incorrect in this suggestion, one of the best longitudinal studies of
the impact of bereavement found little evidence for impact of a
shared environment [6]. There are also opportunities for surviving
partners to assess and tackle their own health risks during the time
from cancer diagnosis to death. Although there is increasing
emphasis on good generalist and specialist palliative care for those
with advanced progressive illness without a cancer diagnosis [28],
many difficulties remain in making this possible. Our findings
suggest there may be benefits for carers as well as cancer patients
in pursuing the further development of such care for those in the
last year of life and those close to them.
General practitioners may play an important part in reducing
mortality after bereavement. In the 1980s it was reported that 76%
of widowed people had at least one consultation with their family
doctor in the five to seven months after the death, despite it being
uncommon for bereaved patients to have any record of the
bereavement in their GP case-notes [29]. Such attendance figures
are likely to be even higher today [30] as it appears that most
bereaved patients welcome the involvement of their family doctor
[31]. The GP may have had an even greater impact on our
exposed group as our study design means that each dyad was
registered with the same general practice. When the same GP has
been managing cancer in the lost loved one, he or she is more
likely to have also helped the bereaved. This is borne out by our
results on use of primary care services and is supported by other
evidence that relatives of patients who receive terminal care at the
same practice fare best, with most being visited by the GP over the
year after the death [32]. Our finding of an increase in receipt of
prescriptions for antidepressants and, in particular, hypnotics, both
before the death of the cohabitee and thereafter, confirm that this
is a very stressful time for people and that they suffer in particular
from insomnia. Unfortunately, there is little evidence for
effectiveness of hypnotics in this setting [33].
Table 3. Mortality, incident# prescriptions for psychotropic medication and consultations with GP after cancer death/index date.
Outcome Unadjusted IRR(95%CI)* Adjusted IRR(95%CI)*
All cause mortality 0.70 (0.67–0.73) 0.71 (0.68–0.74)1
Incident hypnotic prescription 2.52 (1.95–3.24) 2.44 (1.89–3.14)2
Incident antidepressant prescription 2.02 (1.66–2.47) 1.87 (1.53–2.29)3
Incident anti psychotic prescription 1.02 (0.53–1.97) 0.95 (0.49–1.84)4
Consultation with GP 1.08 (1.08–1.09) 1.06 (1.06–1.07)5
#new courses, not prescribed in the 6 months before the death/index date.
*Reference group unexposed.
1 5Adjusted for age, gender, number of non-psychotropic prescriptions 6 months prior to cancer death/index date, use of psychotropic medication 6 months prior to
cancer death/index date, smoking, alcohol and area deprivation score.
2 3 4Adjusted for age, gender number of non-psychotropic prescriptions 6 months prior to cancer death/index date, smoking, alcohol and area deprivation score.
doi:10.1371/journal.pone.0052561.t003
Figure 1. Kaplan-Meier survival probabilities in exposed and unexposed groups after cancer death/index date.
doi:10.1371/journal.pone.0052561.g001
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Our study has a number of strengths and limitations. This study
is based on a very large cohort of people bereaved after the death
of a person with cancer and not from couples volunteering for a
study of bereavement. They were matched on age and sex with an
even larger cohort of controls and data were available for 6
months before the death/index date. Thus the sample was not
affected by selection, recall and non-response biases that have
limited many studies of bereavement. Use of Poisson regression
models, with our main outcomes modelled as time-dependent,
allowed for unbiased estimates of the effects of bereavement while
reducing bias caused by differential lengths of follow-up. General
practice may be an important confounder in that is associated with
the exposure and the outcomes. Thus, we used a random effects
approach, which took account of the potential clustering effects of
general practices. Our main limitation is selection of participant
dyads. We cannot be certain that every participant selected was in
a coupled relationship (partners or spouses) with each cohabitee;
some may have been blood relatives or friends. However, the
disparity of sex in 98% of the pairs strongly suggests that the
overwhelming majority were cohabiting couples. Furthermore,
this limitation can be applied equally to both cohorts. We may also
have missed couples living with offspring older than 18 years.
However, once again this would have affected both cohorts. The
apparent psychological stress reflected in the increased prescrip-
tions also gives grounds for confidence that we have selected
couples where the death of the cohabitee had a major impact
suggesting that most were emotionally close. We shall also not
have captured bereaved people not registered with general
practitioners. This limitation, however, is likely to be very small,
given that on average 98% of people in England are registered
with a general practitioner and that older people, and particularly
those with a sick person in the household, are more likely to be
registered. Bereaved people who leave their practice (and thus no
longer contributed to follow-up data) might be a group at higher
risk of death, for example they may include people who can no
longer care for themselves and are admitted to residential homes,
or move to join their families. We could not trace death
certification in people who left the practices as the THIN data
are anonymised. To a certain extent, however, this may also have
been the case for older people who left the comparison cohort.
Although there were some differences between the exposed and
unexposed cohorts at the baseline, adjustments in the statistical
model would have taken these into account. At first sight, 15,748
cancer deaths is lower than expected for a total practice
population of close to nine million patients. The main reason
why we have a smaller sample of deaths is because our entry
criterion required that the deceased have lived with another adult.
Many of those who die from cancer will be living alone as they are
widowed or single and do not live with other family members. The
other reason is that our cohort is dynamic, so even though there
are nine million patients not all were a part of it for the full 15
years. Finally, there may be some cancer deaths that we did not
capture as we could not identify the cause of death.
The main focus of the research was on the period after the
death (or index date in the comparison patients). The 6 months
before the death/index date was chosen as a consistent baseline
against which we could measure change. In order to consider data
on covariates, a period is needed in which patients are registered
with GP. Although an alternative approach would have been to
start each cancer dyad at the time of the cancer diagnosis, we
would have had a greatly variable time period before the death (in
some cases more than a decade), which would not always have
been informative since there are many hidden biases (e.g. socio-
economic status) for when patients are diagnosed. The same
partner might not have been with the deceased throughout this
time. Finally it would have made the selection of a start point for
control patients inconsistent.
In conclusion, although bereavement led to a higher rate of
prescription of psychotropic medication and GP attendances,
people living with a partner who dies of cancer appear to have a
reduced risk of all cause mortality. Primary care practitioners need
to be aware of the increased consultations with cohabiters of
people who have recently died from cancer even if the risk of death
in the cohabiters is reduced. The tendency to use psychotropic
medication such as antidepressant and hypnotic soon after the
death of a person with cancer needs further research evaluation.
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